MedTrace Logo

Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults

NCT01267058 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2010-12-24

No results posted yet for this study

Summary

The aim of the study is to assess the safety and immunogenicity of GlaxoSmithKline Biologicals' (formerly known as SmithKline Beecham Biologicals) combined diphtheria-tetanus-acellular pertussis vaccine in healthy adults, from the age of 18 onwards, in Australia.

Conditions

  • Diphtheria
  • Pertussis
  • Tetanus

Interventions

BIOLOGICAL

GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine

Intramuscular, single dose

BIOLOGICAL

GSK Biologicals' acellular pertussis vaccine

Intramuscular, single dose

BIOLOGICAL

Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine

Intramuscular, single dose

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1997-09-30
Primary Completion
1998-02-28
Completion
1998-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01267058 on ClinicalTrials.gov